Abstract. Economic feasibility studies for Health-Technology Assessment (HTA) become more and more important over time. While the data situation is quite good in industrialized countries, it is quite hard to predict health economic values in countries with a developing healthcare system. In the Azerbaijan Republic (AR) thereis a problematicdatasituation on theexactepidemiology oft he Congestive Heart Failure (CHF) and a not tooprecisedatasituation on healthcarecost. Thiasworktriestointerpolatethe worth of a disease management program for cardiac diseases in the AR system and understands itself as a “best guess” and methodology to recalculate the effects with a better and growing data situation.Additionally a risk sharing approach implementing better incentive mechanisms was discussed.The entities taken into account by the simulation model were the impacts on heart attack, stroke and heart failure. The Simulation took place atthe simulated AR population with specific morbidity criteria.According to the simulation a per patient gross saving of 323,53 US$ per year was reached over all entities. The real cost saving without a QALY saving effect would be at a 111,33 US$ per year. Taking also the new technology implementation cost into account, a positive return would only be generated over the additional QALY effect. Overall the technology could produce a QALY effect of 8889 QALYs per year in the AR.

Keywords: Azerbaijan Republic,Economic feasibility, Health Economics, Reinsurance, Disease Management, Simulation, Modelling, Cardiac monitoring.

JEL Classification codes: I 15